echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > 448 million dollars!

    448 million dollars!

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Lundbeck announced that it has reached a final agreement with AprilBio of South Korea


    According to the terms of the license agreement, Lundbeck will pay AprilBio a one-time payment of US$16 million in cash


    The press release shows that too many people around the world suffer from brain diseases-complex diseases are often invisible to others, but they have brought huge losses to individuals, families and society


    APB-A1 is a neutralizing anti-CD40L antibody-like drug candidate with an innovative molecular design that blocks the CD40L/CD40 costimulatory interaction


    APB-A1 is a human high-affinity anti-CD40L antibody-like fusion protein designed to inhibit the CD40L/CD40 pathway by neutralizing and activating CD40L on T cells, thereby significantly weakening the initiated immune response


    (The original text has been deleted)

    Reference materials:

    [1] Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases from AprilBio.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.